TRPV4, a close relative of the vanilloid receptor TRPV1, is activated by diverse modalities
such as endogenous lipid ligands, hypotonicity, protein kinases and, possibly, mechanical …

Background. Three full doses of RTS,S/AS01 malaria vaccine provides partial protection
against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization …

Acquired resistance against antimalarial drugs has further increased the need for an effective
malaria vaccine. The current leading candidate, RTS,S, is a recombinant circumsporozoite …

There is significant debate regarding whether B cells and their antibodies contribute to
effective anti-cancer immune responses. Here we show that patients with metastatic but non-…

The generation of high-quality antibody responses to Plasmodium falciparum (Pf) circumsporozoite
protein (PfCSP), the primary surface antigen of Pf sporozoites, is paramount to the …

The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-blocking
vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit parasite …

Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS,S/AS01 is the first, and to date, the only vaccine that has …

The most advanced P. falciparum circumsporozoite protein-based malaria vaccine, RTS,S/AS01
(RTS,S), confers partial protection but with antibody titers that wane relatively rapidly, …

Transmission-blocking vaccines have the potential to be key contributors to malaria
elimination. Such vaccines elicit antibodies that inhibit parasites during their development in …

AP18 1 was recently disclosed as an antagonist of the TRPA1 receptor by the research group
of Patapoutian. However, no detailed structure–activity relationships around 1 have been …